Bone marrow-derived CD133+ or nucleated cells for peripheral artery disease
The aim of this trial is to asses the safety and efficacy of intramuscular injection of either bone marrow-derived CD133+ cells or bone marrow-derived nucleated cells for the treatment of peripheral artery disease.
Read More
Product Information for
Bone marrow-derived CD133+ or nucleated cells for peripheral artery disease